Office Hysteroscopy in Secondary Infertility After Cesarean Section

Role of Office Hysteroscopy in Cases of Secondary Infertility After Cesarean Section

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03166657

Enrollment

Registered

2017-05-25

Start date

2018-03-01

Completion date

2019-06-01

Last updated

2020-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female

Brief summary

All women with history of secondary infertility after caesarean section will be subjected to office hysteroscopy according to Royal college of obstetrics and gynecology guidelines to diagnose any subtle uterine abnormalities not detected by conventional means. Hysteroscopic examination will be done during the proliferation phase of the menstrual cycle. The hysteroscopic evaluation will include assessment of the cervical canal, intrauterine lesions, the endometrium and the uterotubal junction. . If hysteroscopy reveal a lesion, its type, size, location will be recorded. Transvaginal ultrasound will be done after the procedure to detect fluid in the douglas pouch to confirm patent tubes. Asses the uterine scar in details.

Interventions

PROCEDUREoffice hysteroscopy

A speculum is first inserted into the vagina. The hysteroscope is then inserted and gently moved through the cervix into uterus. Carbon dioxide gas or a fluid, such as saline will be put through the hysteroscope into uterus to expand it. The gas or fluid helps see the lining more clearly. The amount of fluid used is carefully checked throughout the procedure

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Patients with secondary infertility more than 2 years after cesarean section. * Normal semen analysis * Normal hysterosalpingography or laparoscopy within 1year * Evidence of ovulation by transvaginal ultrasound

Exclusion criteria

* • Cases with abnormal semen parameters. * Patients with abnormal hysterosalpingography. * Patients with anovulation. * Hormonal disturbances; high level of prolactin, thyroid hormone disturbances, very high or very low follicular stimulating hormone and luteinizing hormone * Patients known to be epileptic or with history of fits. * Cardiac patients ( valve diseases, ischemic, arrhythmic)

Design outcomes

Primary

Measure	Time frame	Description
percentage of patients with abnormal scar findings in hysteroscopy	1 year	color of the scar and presence of niche

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026